LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis GBX 5.72 -0.78 (-12.00%) As of 03:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About Celadon Pharmaceuticals Stock (LON:CEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CEL alerts:Sign Up Key Stats Today's Range 4.30▼ 5.7250-Day Range 3▼ 20.8052-Week Range 2.21▼ 110Volume11,032 shsAverage Volume291,372 shsMarket Capitalization£3.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCeladon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.comRead More… Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CEL Stock News HeadlinesCeladon Pharmaceuticals (LON:CEL) Shares Up 0.8% - Still a Buy?April 30 at 3:49 AM | americanbankingnews.comCeladon Pharmaceuticals Terminates Credit Facility Amid Strategic Financial AdjustmentsApril 8, 2025 | tipranks.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 30, 2025 | Porter & Company (Ad)Celadon Pharmaceuticals Faces Financial Uncertainty Amid Funding DelaysMarch 31, 2025 | tipranks.comAIM WINNERS & LOSERS: Insig AI projects 70% growth in fourth quarterMarch 24, 2025 | lse.co.ukCeladon Pharmaceuticals to Delist From AIMMarch 24, 2025 | marketwatch.comCeladon Pharmaceuticals Secures £1.95 Million Credit Facility to Boost GrowthFebruary 26, 2025 | tipranks.comCeladon Pharmaceuticals Updates on Financial PositionFebruary 12, 2025 | tipranks.comSee More Headlines CEL Stock Analysis - Frequently Asked Questions How have CEL shares performed this year? Celadon Pharmaceuticals' stock was trading at GBX 14 at the start of the year. Since then, CEL stock has decreased by 53.2% and is now trading at GBX 6.56. View the best growth stocks for 2025 here. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Celadon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCommunication Current SymbolLON:CEL CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees2,780Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-4,965,636.99 Net Margins-4,024.62% Pretax MarginN/A Return on Equity-187.26% Return on Assets-34.40% Debt Debt-to-Equity Ratio196.67 Current Ratio1.92 Quick Ratio6.97 Sales & Book Value Annual Sales£123,381.65 Price / Sales32.58 Cash FlowGBX 2.15 per share Price / Cash Flow3.05 Book ValueGBX 3.80 per share Price / Book1.73Miscellaneous Outstanding Shares61,329,971Free FloatN/AMarket Cap£4.02 million OptionableNot Optionable Beta-0.26 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:CEL) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored#1 AI play of the decade…? (The answer will shock you)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.